Skip to main content
SpringerLink
Log in

Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

The purpose of this study was to determine immunological parameters in the peripheral blood that correlate with the clinical effect of interleukin-2 (IL-2) in patients with metastatic renal cell cancer. A group of 26 patients with metastatic renal cell cancer underwent IL-2 treatment using a 36-day schedule with continuous intravenous IL-2 infusion (3 × 106 units m−2 day−1) administered from days 1 to 5 and days 12 to 16. The white blood cell count and the absolute and relative number of neutrophils, lymphocytes, eosinophils and monocytes were recorded six times in peripheral blood during the treatment. Also the blood counts of T cell and NK cell subsets and cells expressing the T cell activation markers IL-2Rα and VLA-1 were measured. The lymphokine-activated killer (LAK) cell cytotoxicity was measured either with or without additional in vitro stimulation by IL-2. Multivariate statistical analysis showed that the clinical responses were related to the administered dose of IL-2, to a low number of blood cells expressing IL-2 receptors and to a reduction in the blood monocyte count (P <0.05).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Afifi AA, Clark V (1984) Computer aided multivariable analysis. Lifetime Learning Publications, Belmont. Calif.

    Google Scholar 

  2. Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA, Hawkins MJ, Atkins MB, Ciobanu N, Ellis TM (1988) Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res 48: 4409

    Google Scholar 

  3. Böyum A (1968) Isolation of leucocytes from human blood. Scand J Clin Lab Invest 21: 77

    Google Scholar 

  4. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J (1973) Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 11: 765

    Google Scholar 

  5. Christensen B, Kieler J, Vilien M, Don P, Wang CY, Wolf H (1984) A classification of human urothelial cells propagated in vitro. Anticancer Res 4: 319

    Google Scholar 

  6. Cohen PJ, Lotze MT, Roberts JR, Rosenberg SA, Jaffe ES (1987) The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol 129: 208

    Google Scholar 

  7. Dimitriu-Bona A, Burmester GR, Waters SJ, Winchester RJ (1983) Human mononuclear phagocyte differentiation antigens: I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. J Immunol 130: 145

    Google Scholar 

  8. Ettinghausen SE, Moore JG, White DE, Plantanias L, Young NS, Rosenberg SA (1987) Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 69: 1654

    Google Scholar 

  9. Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Philip T (1990) Functional and immunophenotypic modifications induced by IL-2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Response Mod 9: 167

    Google Scholar 

  10. Hank JA, Weil-Hillman G, Surfus JE, Sosman JA, Sondel PM (1990) Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Cancer Immunol Immunother 31: 53

    Google Scholar 

  11. Hemler ME (1990) VLA proteins in the integrin family: Structures, functions, and their role on leukocytes. Annu Rev Immunol 8: 365

    Google Scholar 

  12. Hemler ME, Jacobson JG, Brenner MB, Mann D, Strominger JL (1986) VLA-1: A T cell surface antigen which defines a novel late stage of human T cell activation. Eur J Immunol 15: 502

    Google Scholar 

  13. Hermann GG, Petersen KR, Steven K, Zeuthen J (1990) Reduced LAK-cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: Decreased LAK-cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells. J Clin Immunol 10: 311

    Google Scholar 

  14. Hermann GG, Zeuthen J, Claësson MH (1991) LAK cell mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: Cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines. Nat Immun Cell Growth Regul (in press)

  15. Krigel RL, Padavic-Schaller KA, Rudolph AR, Konrad M, Bradley EC, Comis RL (1990) Renal cell carcinoma: Treatment with recombinant interleukin-2 plus beta interferon. J Clin Oncol 8: 460

    Google Scholar 

  16. Miller AB, Hogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207

    Google Scholar 

  17. Mitchel MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC (1988) Effectiveness and tolerability of low-dose cyclophosphamide and low dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 6: 409

    Google Scholar 

  18. Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumors mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161: 1169

    Google Scholar 

  19. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474

    Google Scholar 

  20. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT (1989) Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 49: 7086

    Google Scholar 

  21. Vilien M, Wolf H, Rasmussen F (1981) Follow-up investigations of bladder cancer patients by titration of natural and specific lymphocyte-mediated cytotoxicity. Cancer Immunol Immunother 10: 171

    Google Scholar 

  22. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Tumour Cell Biology, The Fibiger Institute, Danish Cancer Society, Ndr. Frihavnsgade 70, DK-2100, Copenhagen, Denmark

    Gregers G. Hermann & Jesper Zeuthen

  2. Department of Oncology, Herlev University Hospital, DK-2730, Herlev, Denmark

    Poul F. Geertsen & Hans von der Maase

Authors
  1. Gregers G. Hermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Poul F. Geertsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans von der Maase
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jesper Zeuthen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hermann, G.G., Geertsen, P.F., von der Maase, H. et al. Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma. Cancer Immunol Immunother 34, 111–114 (1991). https://doi.org/10.1007/BF01741344

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01741344

Key words

Search

Navigation